Session Title: Vascular Diseases and Diabetic Retinopathy
Session Date/Time: Friday 18/09/2015 | 11:00-12:30
Paper Time: 11:16
First Author: : M.Gajdosova SLOVAKIA
Co Author(s): : M. Ondrejkova L. Sturova Z. Svetlosakova M. Kolvekova B. Lipkova V. Leskova
PURPOSE:To evaluate the efficacy and safety of dexamethasone intravitreal implant (Ozurdex) in eyes with macular edema (ME) due to RVO in Slovakia
Ophtalmology Hospital OFTAL Zvolen, Eye Clinics of University Hospital Bratislava, Bratislava Ružinov, Trenčín, Eye dpt. Žilina, Eye Clinics of University Hospital Martin, Roosevelt Hospital Banská Bystrica, Army Hospital Ružomberok, Eye dpt. Poprad, Ophtalmology dpt. Prešov, Eye Clinic and Ophtalmology dpt. L.Pasteur University Hospital Košice, Slovakia
Retrospective multicenter (12 centers) chart review analysis of 191 eyes of 191 patients (77 (40%) men, 114 (60%) women) treated with Ozurdex implant with at least 12 monhts follow up (mean 19,0 months). We analysed duration of ME, prior and adjunctive ME treatments, number of injections, functional (BCVA), anatomical (CRT) results and adverse events.
Mean duration of ME was 10,6 months. 65% eyes had BRVO, 35% CRVO. 89% were phakic, 15% had glaucoma. Ozurdex was primary treatment in 32%, in 32% received as monotherapy. 30% received first injection within 3 months of diagnosis, 46% after 6 months. 42% received one, 58% two injections. The mean interval between injections was 9,7 months. Mean CRT reduction was: - 224 um, - 141um and - 125 um at 2, 8 and 12 months respectively (p 0.001). At 12 months 55% eyes had reduction more than 100 um . Mean BCVA change was +8 letters , +6 letters and +6 letters at 2, 8 and 12 months respectively (p 0.001). 57% eyes responded with VA improvement. 13% had improvement more than 10 letters, 23% more than 15 letters. More than 15 letters gained 29% eyes with BRVO and 10% with CRVO. Mean BCVA change at 12 months was +8,0 letters for BRVO, +3,0 letters for CRVO. Adverse events: 45% eyes had ME relapse after second injection. 40% eyes had IOP increase (29% transient, 9% permanent). 3% eyes required filtration surgery. Cataract progression was observed in 34%, cataract surgery was performed in 11% eyes.
Our results confirm the effectivity of Ozurdex injections in treatment of ME following RVO, whether used as the first line or after previous treatments. Increased IOP and cataract progression were the most common treatment related adverse events. The risk of IOP increase and subsequent glaucoma surgery is higher in glaucoma patients (p 0.002).